Abstracts

HIV-1 Combinectin BMS-986197: A Long-Acting Inhibitor With Multiple Modes of Action

Long-acting antiretrovirals could provide a useful alternative to daily oral therapy for HIV-1 infected individuals. However, the need for combination therapy and the potential for multiple IV/IM injections or tolerability issues may create roadblocks to this type of therapy. Adnectins are small proteins derived from the 10th type III domain of the human fibronectin protein…

Long-Acting Oral and Parenteral Dosing of MK-8591 for HIV Treatment or Prophylaxis

The potential to enhance adherence with less frequent dosing would represent a major advance for the treatment and prevention of HIV.  MK-8591 is a nucleoside reverse transcriptase translocation inhibitor (NRTTI) with sub-nM potency that is in early stage clinical development. The phosphorylated anabolites of MK-8591, including the active triphosphate (MK-8591-TP), exhibit protracted intracellular persistence in…

Restricted HIV-1 Diversity and Clonal Expansion Following Cytoreductive Chemotherapy

Cytoreductive chemotherapy for malignancies does not lead to consistent changes in HIV-1 DNA or RNA. However, observed reductions in CD4 T cells during chemotherapy suggest that total body reservoirs decrease. We hypothesize that constriction and subsequent oligoclonal expansion of HIV diversity may be a better measure of the reservoir response to cytoreductive therapy or novel…

Virological Remission After ART Interruption in African HIV-1 Seroconverters

Increasing evidence supports virological remission in a subset of individuals after treatment with antiretroviral therapy (ART) in primary HIV infection (PHI). We present the first analysis of treatment interruption (TI) in individuals with PHI in Africa, to explore the prevalence and predictors of post-treatment control (PTC). 137 individuals within 6 months of seroconversion were recruited…

Streamlining Antiretroviral Therapy Uptake: A Stepped-Wedge Cluster Randomized Trial

In Africa, uptake of antiretroviral therapy (ART), even among clinically-eligible patients presenting for care, is often sub-optimal. Common reasons include sluggish diffusion of contemporary evidence about risks of delay (especially among symptomatic patients); overnight CD4 processing and therefore inefficient determination of treatment eligibility; and multiple pre-treatment adherence counseling norms. We designed an intervention targeting prevalent…

A Randomized Trial to Accelerate HIV Care and ART Initiation Following HIV Diagnosis

There is substantial attrition from HIV testing to initiation of care and antiretroviral therapy (ART).  We tested three strategies to accelerate entry-into-care and ART initiation after testing positive at mobile HIV counselling and testing (HCT) units deployed in communities and workplaces in South Africa. We conducted an unmasked individually randomized pragmatic trial.  Following enrollment, participants…

Towards the Second UNAIDS Target: Population-Level ART Coverage in HPTN 071 (PopART)

Background In 2014 UNAIDS set aspirational global targets for ART coverage for people living with HIV. Many countries currently fall below this target. HPTN 071 (PopART), a community randomised trial in Zambia and South Africa (SA), tests the impact on HIV incidence of a household-based combination HIV prevention approach provided by community-HIV-care-providers (CHiPs). CHiPs deliver…